Table 3.
Outcomes | Overall effect | Heterogeneity | ||||
---|---|---|---|---|---|---|
Effect estimate | 95% CI | p-Value | I2(%) | p-Value | ||
Efficacy | mRS(0-2) | 1.327 | 1.093-1.612 | <0.05 | 38.8 | 0.091 |
Rebleeding rate | 1.410 | 1.092-1.822 | <0.05 | 10.6 | 0.337 | |
Mortality | 1.116 | 1.054-1.180 | <0.05 | 36.9 | 0.047 | |
Complete occlusion | 0.375 | 0.308-0.456 | <0.05 | 0.0 | 0.424 | |
Complications | Vasospasm | 0.787 | 0.649-0.954 | <0.05 | 41.1 | 0.060 |
Hydrocephaly | 1.143 | 1.043-1.252 | <0.05 | 30.7 | 0.173 | |
Cerebral infarction | 0.669 | 0.596-0.751 | <0.05 | 18.9 | 0.238 | |
Neuro deficits | 0.720 | 0.582-0.892 | <0.05 | 15.6 | 0.315 |
Note: mRS = Modified Rankin Scale; GOS = Glasgow Outcome Scale